|1.||Vasudevan, Subhash G: 3 articles (08/2014 - 12/2011)|
|2.||Watanabe, Satoru: 3 articles (08/2014 - 12/2011)|
|3.||Rathore, Abhay P S: 3 articles (08/2014 - 12/2011)|
|4.||Ooi, Eng Eong: 3 articles (08/2014 - 12/2011)|
|5.||Sung, Cynthia: 3 articles (08/2014 - 12/2011)|
|6.||Connolly, John: 2 articles (08/2014 - 10/2012)|
|7.||Tan, Kah Hin: 2 articles (08/2014 - 12/2011)|
|8.||Low, Jenny: 2 articles (10/2012 - 12/2011)|
|9.||Durantel, David: 2 articles (08/2009 - 02/2007)|
|10.||Low, Jenny G: 1 article (08/2014)|
12/01/2011 - "Significantly, celgosivir is effective in lethal challenge mouse models that recapitulate primary or secondary antibody-dependent enhanced DENV infection. "
10/01/2012 - "Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial."
02/01/2007 - "One such compound, celgosivir, is currently being evaluated in clinical trials against HCV infection, and encouraging phase IIa data have been disclosed. "
08/01/2009 - "At the time of publication, a phase II trial was underway to investigate the safety, tolerability and antiviral effect of celgosivir in combination with PEGylated IFNalpha2b plus ribavirin for up to 1 year in patients with chronic HCV infection. "
08/01/2009 - "Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection."
|2.||Dengue (Dengue Fever)
08/01/2014 - "Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial."
12/01/2011 - "Together the present study suggests that celgosivir, which has been clinically determined to be safe in humans, may be a valuable candidate for clinical testing in dengue patients."
10/01/2012 - "These results influenced the selection of the dose regimen for a proof-of-concept clinical trial of celgosivir as a treatment against dengue fever."
08/01/2014 - "Although generally safe and well tolerated, celgosivir does not seem to reduce viral load or fever burden in patients with dengue. "
08/01/2014 - "We tested the α-glucosidase inhibitor celgosivir as a treatment for acute dengue fever. "